The Technical Analyst
Profound Medical Corp [PROF]
Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Profound Medical Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.48% $7.67
America/New_York / 19 apr 2024 @ 13:42
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 187.26 mill |
| EPS: | -1.350 |
| P/E: | -5.68 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 24.43 mill |
| Avg Daily Volume: | 0.0401 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.68 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -5.68 | industry: PE 222.16 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-7.35 (-195.82%) $-15.01 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 7.19 - 7.97 ( +/- 5.16%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2012-12-20 | Hofer Michael | Sell | 40 000 | Patriot Minefinders Inc. |
| 2012-12-18 | Hofer Michael | Sell | 40 000 | Patriot Minefinders Inc. |
| 2012-06-19 | Tejada Fred | Buy | 500 000 | Common Shares |
| 2012-06-19 | Blanchet Justin | Buy | 500 000 | Common Shares |
| 2012-06-19 | Schweitzer John H. | Buy | 500 000 | Common Shares |
| INSIDER POWER |
|---|
| 0.00 |
| Last 8 transactions |
| Buy: 3 000 000 | Sell: 80 000 |
Live Trading Signals (every 1 min)
Forecast
1: 13:51 - $7.64
Forecast 2: 14:41 - $7.50
Forecast 3: 15:21 - $7.43
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $7.67 (-1.48% ) |
| Volume | 0.0364 mill |
| Avg. Vol. | 0.0401 mill |
| % of Avg. Vol | 90.84 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PROF
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PROF
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities. The company also offers Sonalleve, a therapeutic platform for the treatment of uterine fibroids and palliative pain relief associated with metastases in bone, as well as non-invasive treatment of uterine fibroids. Profound Medical Corp. is headquartered in Mississauga, Canada.
Latest Press Releases
2024-04-09 07:45:00 - Press Release
Profound Medical To Participate In The 2024 Bloom Burton & Co. Healthcare Investor Conference
Toronto, april 09, 2024 (globe newswire) -- profound medical corp. (nasdaq:prof; tsx:prn) (“profound” or the “company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the company's business at the 2024 bloom burton & co. healthcare investor conference on tuesday, april 16, 2024 at 9:30 a.m. eastern time at the metro toronto convention centre.
2024-03-07 16:05:00 - Press Release
Profound Medical Announces Fourth Quarter And Full Year 2023 Financial Results
Toronto, march 07, 2024 (globe newswire) -- profound medical corp. (nasdaq:prof; tsx:prn) (“profound” or the “company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended december 31, 2023. unless specified otherwise, all amounts in this press release are expressed in u.s. dollars and are presented in accordance with international financial reporting standards as issued by the international accounting standards board.
2024-03-04 16:30:00 - Press Release
Profound Medical To Participate In Barclays 26th Annual Global Healthcare Conference
Toronto, march 04, 2024 (globe newswire) -- profound medical corp. (nasdaq:prof; tsx:prn) (“profound” or the “company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in a fireside chat at the barclays 26th annual global healthcare conference on wednesday, march 13, 2024 at 11:15 a.m. eastern time at the loews miami beach hotel.
2024-02-27 07:45:00 - Press Release
Profound Medical In Collaboration With Siemens Healthineers To Further Expand Physician And Patient Access To The Tulsa Procedure
Toronto, feb. 27, 2024 (globe newswire) -- profound medical corp. (nasdaq:prof; tsx:prn) (“profound” or the “company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that it has entered into a non-exclusive collaboration with siemens healthineers, a global leader in medical technology. the collaboration is aimed at laying the groundwork for profound to begin marketing a complete therapeutics solution, combining its tulsa-pro® system with the magnetom free.max magnetic resonance (“mr”) scanner from siemens healthineers, via profound's own sales force. profound will also continue to market tulsa-pro® as a stand-alone offering, providing its customers with the flexibility to use the technology with the mr hardware of their choice.
2024-02-15 16:30:00 - Press Release
Profound Medical To Release Fourth Quarter And Full Year 2023 Financial Results On March 7 – Conference Call To Follow
Toronto, feb. 15, 2024 (globe newswire) -- profound medical corp. (nasdaq:prof; tsx:prn) (“profound” or the “company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2023 financial results after market close on thursday, march 7, 2024.
Latest News
2024-04-09 07:45:00 - GlobeNewsWire
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
TORONTO, April 09, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2024 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 16, 2024 at 9:30 a.m. Eastern Time at the Metro Toronto Convention Centre.
2024-03-07 23:35:04 - Seeking Alpha
Profound Medical Corp. (PROF) Q4 2023 Earnings Call Transcript
Profound Medical Corp. (NASDAQ:PROF ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Stephen Kilmer – Investor Relations Arun Menawat – Chief Executive Officer Rashed Dewan – Chief Financial Officer Mathieu Burtnyk – Chief Operating Officer Conference Call Participants Rick Wise – Stifel Rahul Sarugaser – Raymond James Michael Sarcone – Jefferies Brian Gagnon – Gagnon Securities Chris Potter – Northern Border Investments Operator Good day, and welcome to the Profound Medical Fourth Quarter and Full Year 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
2024-03-04 16:30:00 - GlobeNewsWire
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024 at 11:15 a.m. Eastern Time at the Loews Miami Beach Hotel.
2024-03-01 13:01:29 - Zacks Investment Research
Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer
Profound Medical (PROF) collaborates with Siemens to boost prostate cancer treatment procedures by combining their technologies.
2024-02-15 16:30:00 - GlobeNewsWire
Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow
TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024.
2024-01-29 10:11:07 - Zacks Investment Research
Profound Medical (PROF) Soars 9.4%: Is Further Upside Left in the Stock?
Profound Medical (PROF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2024-01-26 10:56:04 - Zacks Investment Research
How Much Upside is Left in Profound Medical (PROF)? Wall Street Analysts Think 66.06%
The mean of analysts' price targets for Profound Medical (PROF) points to a 66.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
2023-11-04 11:45:25 - Seeking Alpha
Profound Medical Corp. (PROF) Q3 2023 Earnings Call Transcript
Profound Medical Corp. (NASDAQ:PROF ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET Company Participants Stephen Kilmer - IR Arun Menawat - Chairman and CEO Rashed Dewan - CFO Conference Call Participants Rahul Sarugaser - Raymond James Benjamin Haynor - Alliance Global Partners Nelson Cox - Lake Street Capital Markets Scott McAuley - Paradigm Capital Operator Good day and thank you for standing by. Welcome to the Profound Medical Third Quarter 2023 Financial Results Conference Call.
2023-10-19 16:30:00 - GlobeNewsWire
Profound Medical to Release Third Quarter 2023 Financial Results on November 2 – Conference Call to Follow
TORONTO, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its third quarter 2023 financial results after market close on Thursday, November 2, 2023.
2023-09-19 16:45:00 - GlobeNewsWire
Profound Medical to Participate in the 2023 Cantor Global Healthcare Conference
TORONTO, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company's business at the 2023 Cantor Global Healthcare Conference on Tuesday, September 26, 2023 at 4:55 p.m. Eastern Time in NYC.